MarketCap
Facebook
X
TelegramAnnual report 2022
added 03-20-2023
Athenex ROCE Ratio 2011-2026 | ATNX
Annual ROCE Ratio Athenex
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1076.15 | -294.21 | -38.4 | -50.14 | -70.68 | -115.45 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1076.15 | -294.21 | 84.54 |
Quarterly ROCE Ratio Athenex
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -268.07 | -289.79 | -151.59 | -175.19 | -58.72 | -84.4 | -79.18 | -73.56 | -68.82 | -54.44 | -55.79 | -53.97 | -63.5 | -70.46 | -92.97 | -103.55 | -91.0 | -104.24 | -82.1 | -89.53 | -122.16 | -202.05 | -256.73 | -260.57 | -222.29 | -110.91 | -38.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -38.02 | -289.79 | -123.1 |
ROCE Ratio of other stocks in the Drug manufacturers industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
267.43 | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-190.63 | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
-20.78 | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
3101.1 | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
-249.5 | - | - | $ 50.1 M | USA |
 |
Canopy Growth Corporation
CGC
|
-24.04 | $ 1.06 | -0.93 % | $ 114 M |  Canada |
 |
Endo International plc
ENDP
|
7.34 | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
121.85 | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
-184.26 | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
-4.18 | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
-10.43 | $ 2.6 | -1.14 % | $ 1.35 B | Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
-57.41 | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
-116.71 | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
-59.23 | $ 0.55 | -3.51 % | $ 9.61 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
-8.06 | $ 4.58 | -5.37 % | $ 64.4 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-39.6 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.61 | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-29.88 | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
-23.09 | $ 3.48 | -6.2 % | $ 86.3 M | Canada |
 |
Harrow Health
HROW
|
58.18 | $ 38.6 | -27.96 % | $ 1.42 B | USA |
 |
Emergent BioSolutions
EBS
|
-111.87 | $ 8.92 | -0.78 % | $ 457 M | USA |
 |
ProPhase Labs
PRPH
|
32.97 | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
-176.47 | $ 11.9 | 1.06 % | $ 845 M | USA |
 |
Radius Health
RDUS
|
21.53 | - | - | $ 1.42 B | USA |
 |
Evolus
EOLS
|
141.36 | $ 4.13 | -3.73 % | $ 266 M | USA |
 |
Bausch Health Companies
BHC
|
-94.23 | $ 5.73 | -3.7 % | $ 2.09 B | Canada |
 |
Lannett Company
LCI
|
70.21 | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
34.66 | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
-0.49 | $ 2.87 | -4.33 % | $ 378 M | USA |
 |
OrganiGram Holdings
OGI
|
-35.84 | $ 1.37 | -3.52 % | $ 402 M | Canada |
 |
Perrigo Company plc
PRGO
|
-14.92 | $ 11.39 | -7.89 % | $ 1.58 B | USA |
 |
Rockwell Medical
RMTI
|
-31.33 | $ 0.9 | -0.12 % | $ 21 M | USA |
 |
Sundial Growers
SNDL
|
-68.48 | $ 1.53 | 0.66 % | $ 3.37 M | Canada |
 |
TherapeuticsMD
TXMD
|
-29.1 | $ 2.22 | -0.89 % | $ 23.2 M | USA |
 |
Veru
VERU
|
-114.23 | $ 2.52 | -3.82 % | $ 340 M | USA |
 |
Viatris
VTRS
|
3.74 | $ 14.89 | -5.16 % | $ 17.9 B | USA |
 |
cbdMD
YCBD
|
-235.96 | $ 0.77 | -4.37 % | $ 3.32 M | USA |
 |
Pacira BioSciences
PCRX
|
-9.43 | $ 22.1 | 3.85 % | $ 1.02 B | USA |
 |
PetIQ
PETQ
|
5.46 | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
26.27 | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-114.37 | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
-6.09 | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-121.49 | $ 4.67 | -3.51 % | $ 141 M | USA |
 |
SCYNEXIS
SCYX
|
99.6 | $ 0.75 | 0.33 % | $ 35.9 M | USA |
 |
Solid Biosciences
SLDB
|
-81.9 | $ 5.96 | -3.87 % | $ 243 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-84.11 | $ 2.75 | -3.17 % | $ 3.41 M | USA |
 |
Tricida
TCDA
|
-70162.39 | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-41.31 | $ 7.36 | -3.16 % | $ 4.55 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
-76.25 | - | - | $ 55.5 M | USA |